Cynosure Shares Down 11.1% Since SmarTrend's Sell Call (CYNO)
Comtex SmarTrend(R) - Fri Apr 11, 10:17AM CDT
SmarTrend identified a Downtrend for Cynosure (NASDAQ:CYNO) on March 20th, 2014 at $29.39. In approximately 3 weeks, Cynosure has returned 11.08% as of today's recent price of $26.13.
AngioDynamics Q3 Earnings Flat but Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:28AM CDT
ANGO lowered its adjusted EPS guidance for fiscal 2014 to a range of 60 to 63 cents from the prior range of 63 to 67 cents.
Delcath Systems (DCTH) Worth Watching: Stock Soars 20.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:25AM CDT
Delcath Systems was a big mover last session, with shares surging over 20% on the day.
Masimo Reports Encouraging PVI Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 5:40PM CDT
The results demonstrated that MASI's non-invasive PVI parameter helps clinicians optimize fluid administration for abdominal surgical patients under combined general and epidural anesthesia.
Delcath Systems Shares Tank on Stock Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 1:50PM CDT
Delcath has been going through a rough patch after it failed to win approval from U.S. Food and Drug Administration (FDA) for its Melblez liver cancer therapy device.
Financial Results Announcement, Stock Movement, Presentations, and Acquisition - Analyst Notes on Universal Health Services, Tenet, Cynosure, Albany Molecular Research, and Enanta
PR Newswire - Thu Apr 10, 9:49AM CDT
Today, Analysts Review released its analysts' notes regarding Universal Health Services, Inc. (NYSE: UHS), Tenet Healthcare Corp. (NYSE: THC), Cynosure, Inc. (NASDAQ: CYNO), Albany Molecular Research Inc. (NASDAQ: AMRI), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cepheid (CPHD) Looks Good: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:04AM CDT
Cepheid was a big mover last session, as the company saw its shares rise over 5% on the day.
Intuitive Surgical (ISRG) Crumbles: Stock Falls by 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:34AM CDT
Shares of Intuitive Surgical fell nearly 7% on the day. This continues the recent trend of the company, as the stock is now trading within the volatile price range of $422.1 to $540.6 in the past one-month time frame.
Varian Medical Systems Closes Velocity Software Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 2:20PM CDT
Post-acquisition, VAR expects its global sales, service and support network to contribute to faster and deeper market penetration for the Velocity product.
Intuitive Surgical Expects Lower Q1 Revs, Shares Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 1:50PM CDT
Per Intuitive Surgical, the deferrals will reduce Systems revenues by roughly $24 million and Instruments and Accessories revenues by $2 million.
Echo Therapeutics Slips to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 07, 1:50PM CDT
Echo Therapeutics' fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents.
Thoratec Slapped with Class I Recall for HeartMate Controller - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 12:20PM CDT
THOR initiated its recall of HeartMate II left ventricular assist device (LVAD) after sending safety advisory to hospitals regarding the use of its pocket system controller for the device.
Intuitive Surgical Recalls Cannulae, Shares Shoot Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 3:35PM CDT
Intuitive Surgical stated that if inspection reveals damaged devices, they should be quarantined and returned to the company for replacement
DexCom Shares Fall on FDA Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 2:30PM CDT
Since the revelation of the warning letter, DexCom's shares dropped 5.7% to close at $41.95 yesterday.
New Taker for Varian's PerfectPitch Couch - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 5:40PM CDT
The PerfectPitch robotic couch has been introduced by the hospital as an integrated element of VAR's latest TrueBeam 2.0 system used to optimize radiotherapy treatments.
FDA Clears Intuitive Surgical's New da Vinci System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 2:10PM CDT
Intuitive Surgical revealed that the new robotic system, known as da Vinci Xi, has longer instrument shafts enabling greater reach for surgery
Intuitive Surgical (ISRG) in Focus: Stock Rises 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:25AM CDT
Intuitive Surgical was a big mover last session, with shares rising nearly 13% on the day.
Cynosure Announces 35 Clinical Research Presentations at 34th ASLMS Annual Conference
PR Newswire - Wed Apr 02, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that 21 oral abstracts and 14 e-posters are scheduled for presentation this week at LASER 2014, the 34th Annual Scientific Conference of the American Society for Laser Medicine and Surgery (ASLMS). LASER 2014 takes place today through April 6 at the Phoenix Convention Center/Sheraton Phoenix Downtown Hotel in Phoenix, Arizona.
Study: Teleflex Catheter Reduces Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:20PM CDT
The study, conducted by Leonardo Lorente M.D., Ph.D. and his colleagues independently, found that the Teleflex's ARROW catheter with ARROWg+ard Blue PLUS Technology lowers the risk of catheter-related bloodstream infections.
Teleflex Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 1:50PM CDT
An encouraging guidance, increased M&A activity and stronger operating leverage represent a potential upside for Teleflex going forward.